Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Executive Summary

Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.

Advertisement

Related Content

Purdue NDA For Oxycodone/Naloxone Combo Tests New FDA Policy
Pfizer’s Remoxy Clears Manufacturing Hurdle, Still Needs BE, Abuse-Potential Studies
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back
COPD Market Snapshot: New Products, Limited Differentiation
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify
FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake
Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel